230 related articles for article (PubMed ID: 23066034)
21. Ellagic acid inhibits RANKL-induced osteoclast differentiation by suppressing the p38 MAP kinase pathway.
Rantlha M; Sagar T; Kruger MC; Coetzee M; Deepak V
Arch Pharm Res; 2017 Jan; 40(1):79-87. PubMed ID: 27384064
[TBL] [Abstract][Full Text] [Related]
22. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
23. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
24. p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells.
Browne AJ; Göbel A; Thiele S; Hofbauer LC; Rauner M; Rachner TD
Cell Death Dis; 2016 Feb; 7(2):e2119. PubMed ID: 26913608
[TBL] [Abstract][Full Text] [Related]
25. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
Gai D; Chen JR; Stewart JP; Nookaew I; Habelhah H; Ashby C; Sun F; Cheng Y; Li C; Xu H; Peng B; Garg TK; Schinke C; Thanendrarajan S; Zangari M; Chen F; Barlogie B; van Rhee F; Tricot G; Shaughnessy JD; Zhan F
J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 35881476
[TBL] [Abstract][Full Text] [Related]
26. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.
Delgado-Calle J; Anderson J; Cregor MD; Hiasa M; Chirgwin JM; Carlesso N; Yoneda T; Mohammad KS; Plotkin LI; Roodman GD; Bellido T
Cancer Res; 2016 Mar; 76(5):1089-100. PubMed ID: 26833121
[TBL] [Abstract][Full Text] [Related]
27. SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth.
Feng R; Anderson G; Xiao G; Elliott G; Leoni L; Mapara MY; Roodman GD; Lentzsch S
Blood; 2007 Mar; 109(5):2130-8. PubMed ID: 17095620
[TBL] [Abstract][Full Text] [Related]
28. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
29. Muramyl dipeptide enhances lipopolysaccharide-induced osteoclast formation and bone resorption through increased RANKL expression in stromal cells.
Ishida M; Kitaura H; Kimura K; Sugisawa H; Aonuma T; Takada H; Takano-Yamamoto T
J Immunol Res; 2015; 2015():132765. PubMed ID: 26000311
[TBL] [Abstract][Full Text] [Related]
30. (2S)-2'-Methoxykurarinone inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling.
Kim JY; Kim JY; Kim JJ; Oh J; Kim YC; Lee MS
Biol Pharm Bull; 2014; 37(2):255-61. PubMed ID: 24492722
[TBL] [Abstract][Full Text] [Related]
31. C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis.
Yang J; Liu Z; Liu H; He J; Yang J; Lin P; Wang Q; Du J; Ma W; Yin Z; Davis E; Orlowski RZ; Hou J; Yi Q
Sci Signal; 2017 Dec; 10(509):. PubMed ID: 29233917
[TBL] [Abstract][Full Text] [Related]
32. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
33. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
[TBL] [Abstract][Full Text] [Related]
34. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
Ishitsuka K; Hideshima T; Neri P; Vallet S; Shiraishi N; Okawa Y; Shen Z; Raje N; Kiziltepe T; Ocio EM; Chauhan D; Tassone P; Munshi N; Campbell RM; Dios AD; Shih C; Starling JJ; Tamura K; Anderson KC
Br J Haematol; 2008 May; 141(5):598-606. PubMed ID: 18397345
[TBL] [Abstract][Full Text] [Related]
35. CaMKII(δ) regulates osteoclastogenesis through ERK, JNK, and p38 MAPKs and CREB signalling pathway.
Lu DZ; Dong W; Feng XJ; Chen H; Liu JJ; Wang H; Zang LY; Qi MC
Mol Cell Endocrinol; 2020 May; 508():110791. PubMed ID: 32173349
[TBL] [Abstract][Full Text] [Related]
36. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
37. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
38. [Mechanisms for formation of myeloma bone disease].
Yata K; Abe M; Matsumoto T
Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
[TBL] [Abstract][Full Text] [Related]
39. Dual Role of Cyanidin-3-glucoside on the Differentiation of Bone Cells.
Park KH; Gu DR; So HS; Kim KJ; Lee SH
J Dent Res; 2015 Dec; 94(12):1676-83. PubMed ID: 26350961
[TBL] [Abstract][Full Text] [Related]
40. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
